Does an alteration of dialyzer design and geometry affect biocompatibility parameters?

Hemodialysis International

Volumn 10, Issue 2, 2006, Pages 201-208

  Opatrný Jr , Karel ^a   Kroužecký, Aleš ^a   Polanská, Kamila ^a   Mareš, Jan ^a   Tomšů, Martina ^a   Bowry, Sudhir K ^b   Vienken, Jörg ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Biocompatibility; Complement; Dialysis; Polysulfone; Thrombogenicity

Indexed keywords

COMPLEMENT COMPONENT C5A; D DIMER; HEPARIN; POLYSULFONE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; THROMBOPLASTIN;

ADULT; AGED; ANALYZER; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSIS MEMBRANE; DRUG BLOOD LEVEL; EQUIPMENT DESIGN; FEMALE; FIBRINOLYSIS; GEOMETRY; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; LEUKOPENIA; LONG TERM CARE; MALE; MOLECULAR SIZE; PARTIAL THROMBOPLASTIN TIME; PROCESS OPTIMIZATION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOGENICITY;

AGED; AGED, 80 AND OVER; BIOCOMPATIBLE MATERIALS; BLOOD CHEMICAL ANALYSIS; CROSS-OVER STUDIES; EQUIPMENT SAFETY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MATERIALS TESTING; MEMBRANES, ARTIFICIAL; MIDDLE AGED; MONITORING, PHYSIOLOGIC; POLYMERS; PROSPECTIVE STUDIES; REFERENCE VALUES; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY; SULFONES;

EID: 33645295460     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.00095.x     Document Type: Article

References (27)

1. Ronco C, Bowry SK, Brendolan A, et al. Hemodialyzer: From macro-design to membrane nanostracture; the case of the FX-class of hemodialyzers. Kidney Int. 2002; 61 (Suppl 80): S126-S142.
2. Ronco C, Bowry S. Nanoscale modulation of the pore dimensions, size distribution and structure of a new polysulfone-based high-flux dialysis membrane. Int J Artif Organs. 2001; 20: 726-735.
3. Kuelz M, Nederlof B, Schneider H. In vitro and in vivo evaluation of a new dialyzer. Nephrol Dial Transplant. 2002; 17: 1475-1479.
4. Grooteman MP, Nube MJ, van Limbeek J, van Houte AJ, Daha MR, van Geelen JA. Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer. A randomized crossover comparison between cellulose triacetate and polysulphone. ASAIO J. 1995; 41: 215-220.
5. Bloembergen WE, Hakim RM, Stannard DC, et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis. 1999; 33: 1-10.
6. Tayeb JS, Provenzano R, El-Ghoroury M, et al. Effect of biocompatibility of hemodialysis membranes on serum albumin levels. Am J Kidney Dis. 2000; 35: 606-610.
7. Bommer J, Becker KP, Urbaschek R. Potential transfer of endotoxin across high-flux polysulfone membranes. J Am Soc Nephrol. 1996; 7: 883-888.
8. Ward RA. Effects of haemodialysis on coagulation and platelets: Are we measuring membrane biocompatibility? Nephrol Dial Transplant. 1995; 10 (Suppl. 10): 12-17.
9. Mujais SK, Schmidt B, Hacker H, Opatrny K Jr., Gurland HJ. Synthetic modification of PAN membrane: Biocompatibility and functional characterization. Nephrol Dial Transplant. 1995; 10 (Suppl 3): 46-51.
10. Hoenich NA, Stamp S, Roberts SJ. A microdomain-structured synthetic high-flux hollow-fiber membrane for renal replacement therapy. ASAIO J. 2000; 46: 70-75.
11. Elisaf MS, Germanos NP, Bairaktari HT, Pappas MB, Koulouridis EI, Siamopoulos KC. Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol. 1997; 17: 153-157.
12. Lai KN, Ho K, Cheung RC, et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs. 2001; 24: 447-455.
13. Opatrný K Jr, Bouda M, KohoutkováL, Vít L, Šefrna F. A clinical study to assess the effect of heparin in dialyzer rinsing solution. Int J Artif Organs. 1997; 20: 112 -118.
14. Culleton BF, Wilson PWF. Thrombogenic risk factors for cardiovascular disease in dialysis patients. Semin Dial. 1999; 12: 117-125.
15. Assouad M, Eknoyan G. Does the choice of renal replacement therapy adversely affect the hypercoagulability associated with renal disease? Am J Nephrol. 1998; 18: 175-178.
16. Lane DA, Bowry SK. The scientific basis for selection of measures of thrombogenicity. Nephrol Dial Transplant. 1994; 9 (Suppl. 2): 18-28.
17. Lindhout T. Biocompatibility of extracorporeal blood treatment. Selection of haemostatic parameters. Nephrol Dial Transplant. 1994; 9 (Suppl. 2): 83-89.
18. Schulze G, Hollmann S, Sinah P. Formation of thrombin-antithrombin III complex using polyamide and Hemophan dialyzers. Int J Artif Organs. 1992; 15: 370-373.
19. Kolb G, Fischer W, Seitz R, et al. Hemodialysis and blood coagulation: The effect of hemodialysis on coagulation factor XIII and thrombin-antithrombin III complex. Nephron. 1991; 58: 106-108.
20. Opatrný K Jr, SulkováS, Lopot F, Vít L, Válek A, Opatrný K. A clinical study on high-flux cuprammonium rayon haemodialysis membranes. Artif Organs. 1993; 17: 971-976.
21. Cheung AK, Parker CJ, Wilcox LA, Janatova J. Activation of complement by hemodialysis membranes: Polyacrylonitrile binds more C3a than Cuprophan. Kidney Int. 1990; 37: 1055-1059.
22. Opatrný Jr. K. Vít L, Opatrná S, et al. Hemocompatibility in hemodialysis and erythropoietin therapy. Artif Organs. 1995; 19: 814-820.
23. Hoerl WH. Hemodialysis membranes: Interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol. 2002; 13 (Suppl. 1): S62-S71.
24. Opatrný K Jr. Clinical importance of biocompatibility and its effect on hemodialysis treatment. Nephrol Dial Transplant. 2003; 18 (Suppl. 5): 41-44.
25. Stefoni S, Coli L, Cianciolo G, et al. Inflammatory response of a new synthetic dialyzer membrane. A randomized cross-over comparison between polysulfone and helixone. Int J Artif Organs. 2003; 26: 26-32.
26. Lonnemann G, Novick D, Rubinstein M, Passlick-Deetjen J, Lang D, Dinarello CA. A switch to high-flux Helixone ® membranes reverses suppressed interferon-gamma production in patients on low-flux dialysis. Blood Purif. 2003; 21: 225-231.
27. Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S. Differences in the permeability of high-flux dialyser membranes for bacterial pyrogens. Clin Nephrol. 2003; 59: 447-454.